Contact

All Stories

  1. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol

    Article • Gynecologic Oncology, October 2025, Elsevier

    Professor David Scott Miller

  2. Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

    Article • June 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  3. Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

    Article • June 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  4. Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

    Article • June 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  5. Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

    Article • June 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  6. Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

    Article • June 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  7. Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

    Article • June 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  8. Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

    Article • June 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  9. E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO).

    Article • Journal of Clinical Oncology, June 2025, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  10. Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial

    Article • Clinical Cancer Research, April 2025, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  11. Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma

    Article • Gynecologic Oncology Reports, April 2025, Elsevier

    Professor David Scott Miller

  12. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258

    Article • Gynecologic Oncology, February 2025, Elsevier

    Professor David Scott Miller

  13. Molecular Classification of Endometrial Cancers (EC) and Association with Relapse-Free Survival (RFS) and Overall Survival (OS) Outcomes: Ancillary Analysis of GOG-0258

    Article • January 2025, Elsevier

    Professor David Scott Miller

  14. Surgical Staging Identifies Occult Metastases in Over 50% of Uterine-Confined Carcinosarcoma

    Article • January 2025, Elsevier

    Professor David Scott Miller

  15. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma

    Article • Journal of Clinical Oncology, December 2024, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  16. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14

    Article • Gynecologic Oncology, November 2024, Elsevier

    Professor David Scott Miller

  17. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024

    Article • Journal of the National Comprehensive Cancer Network, October 2024, Harborside Press, LLC

    Professor David Scott Miller

  18. Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer

    Article • Gynecologic Oncology, September 2024, Elsevier

    Professor David Scott Miller

  19. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

    Article • Gynecologic Oncology, June 2024, Elsevier

    Professor David Scott Miller

  20. Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).

    Article • Journal of Clinical Oncology, June 2024, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  21. Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis.

    Article • Journal of Clinical Oncology, June 2024, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  22. Social determinants of health in uterine carcinosarcoma

    Article • Gynecologic Oncology, May 2024, Elsevier

    Professor David Scott Miller

  23. Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial

    Article • Journal of Clinical Oncology, April 2024, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  24. Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279

    Article • Journal of Clinical Oncology, April 2024, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  25. 187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

    Article • March 2024, BMJ

    Professor David Scott Miller

  26. Predicting Vte and Utility of Thromboprophylaxis in Metastatic and Recurrent Cervical Cancer

    Article • January 2024, Elsevier

    Professor David Scott Miller

  27. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

    Article • Journal of Clinical Oncology, September 2023, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  28. Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma (LBA 5)

    Article • Gynecologic Oncology, September 2023, Elsevier

    Professor David Scott Miller

  29. A phase II trial evaluating cisplatin and gemcitabine concurrent with intensity-modulated radiation therapy (IMRT) for the treatment of locally advanced squamous cell carcinoma of the vulva: NRG oncology trial #279 (004)

    Article • Gynecologic Oncology, September 2023, Elsevier

    Professor David Scott Miller

  30. Fertility-sparing Treatment for Early-stage Endometrial Cancer is Safe and Does Not Compromise Oncological Outcome

    Article • July 2023, Cambridge University Press

    Professor David Scott Miller

  31. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice

    Article • European Journal of Cancer, June 2023, Elsevier

    Professor David Scott Miller

  32. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

    Article • Journal of Clinical Oncology, April 2023, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  33. Supplementary Figures 1-6 from Epigenetic Repression of <i>microRNA-129-2</i> Leads to Overexpression of <i>SOX4</i> Oncogene in Endometrial Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  34. Supplementary Figures 1-6 from Epigenetic Repression of <i>microRNA-129-2</i> Leads to Overexpression of <i>SOX4</i> Oncogene in Endometrial Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  35. Data from Epigenetic Repression of <i>microRNA-129-2</i> Leads to Overexpression of <i>SOX4</i> Oncogene in Endometrial Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  36. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma

    Article • Expert Review of Anticancer Therapy, March 2023, Taylor & Francis

    Professor David Scott Miller

  37. Isolated para-aortic nodal recurrence after treatment of early stage cervical carcinoma

    Article • Gynecologic Oncology, March 2023, Elsevier

    Professor David Scott Miller

  38. Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

    Article • Cancers, January 2023, MDPI AG

    Professor David Scott Miller

  39. Contributors

    Article • January 2023, Elsevier

    Professor David Scott Miller

  40. Adenocarcinoma of the uterine corpus and sarcomas of the uterus

    Article • January 2023, Elsevier

    Professor David Scott Miller

  41. 17 Pre-operative patient characteristics predict outpatient opioid use

    Article • Gynecologic Oncology Reports, December 2022, Elsevier

    Professor David Scott Miller

  42. 18 Obesity as a post-operative risk factor for women undergoing open radical hysterectomy

    Article • Gynecologic Oncology Reports, December 2022, Elsevier

    Professor David Scott Miller

  43. 45 Disparities in carcinosarcoma: public vs private hospital system

    Article • Gynecologic Oncology Reports, December 2022, Elsevier

    Professor David Scott Miller

  44. O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775

    Article • December 2022, BMJ

    Professor David Scott Miller

  45. 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

    Article • October 2022, BMJ

    Professor David Scott Miller

  46. 2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma

    Article • October 2022, BMJ

    Professor David Scott Miller

  47. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

    Article • Journal of the National Comprehensive Cancer Network, September 2022, Harborside Press, LLC

    Professor David Scott Miller

  48. 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

    Article • Annals of Oncology, September 2022, Elsevier

    Professor David Scott Miller

  49. Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study

    Article • Cancers, August 2022, MDPI AG

    Professor David Scott Miller

  50. Isolated para-aortic nodal metastasis or recurrence absent after radical hysterectomy for stage IA-IIA cervical carcinoma (401)

    Article • Gynecologic Oncology, August 2022, Elsevier

    Professor David Scott Miller

  51. Pembrolizumab in pretreated advanced, metastatic cervical, vulvar, vaginal carcinoma (325)

    Article • Gynecologic Oncology, August 2022, Elsevier

    Professor David Scott Miller

  52. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

    Article • Journal of Clinical Oncology, June 2022, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  53. 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)

    Article • Annals of Oncology, June 2022, Elsevier

    Professor David Scott Miller

  54. Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/K...

    Article • Journal of Clinical Oncology, June 2022, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  55. Lynch Syndrome Identification in Endometrial Cancer Patients: Should Universal Screening be Used for all Histologies?

    Article • Current Women s Health Reviews, May 2022, Bentham Science Publishers

    Professor David Scott Miller

  56. Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer

    Article • Obstetrical & Gynecological Survey, May 2022, Wolters Kluwer Health

    Professor David Scott Miller

  57. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2022, New England Journal of Medicine (NEJM/MMS)

    Professor David Scott Miller

  58. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

    Article • Journal of Clinical Oncology, January 2022, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  59. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study

    Article • Gynecologic Oncology, January 2022, Elsevier

    Professor David Scott Miller

  60. Risk factors associated with 30-day postoperative complications following contemporary vulvectomies with inguinofemoral lymphadenectomies for gynecologic cancers

    Article • Gynecologic Oncology, January 2022, Elsevier

    Professor David Scott Miller

  61. Corrigendum to “Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis” [Gynecologic Oncology 162 (2021) 532–538]

    Article • Gynecologic Oncology, December 2021, Elsevier

    Professor David Scott Miller

  62. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study

    Article • Gynecologic Oncology, December 2021, Elsevier

    Professor David Scott Miller

  63. O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775

    Article • November 2021, BMJ

    Professor David Scott Miller

  64. O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors

    Article • November 2021, BMJ

    Professor David Scott Miller

  65. 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775)

    Article • October 2021, BMJ

    Professor David Scott Miller

  66. Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis

    Article • Gynecologic Oncology, September 2021, Elsevier

    Professor David Scott Miller

  67. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

    Article • Annals of Oncology, September 2021, Elsevier

    Professor David Scott Miller

  68. A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer

    Article • Gynecologic Oncology, August 2021, Elsevier

    Professor David Scott Miller

  69. Risk factors associated with 30-day postoperative complications following contemporary pelvic exenterations for gynecologic cancer

    Article • Gynecologic Oncology, August 2021, Elsevier

    Professor David Scott Miller

  70. Delayed time to surgery with hormonal treatment does not adversely impact outcomes in women with low-grade endometrioid endometrial cancer

    Article • Gynecologic Oncology, August 2021, Elsevier

    Professor David Scott Miller

  71. Is there a need for consultant team for bowel resection? An evaluation of surgical outcomes of bowel resection at time of ovarian cytoreductive surgery

    Article • Gynecologic Oncology, August 2021, Elsevier

    Professor David Scott Miller

  72. Perioperative risk factors and postoperative outcomes following pelvic exenterations for gynecologic versus non-gynecologic malignancies

    Article • Gynecologic Oncology, August 2021, Elsevier

    Professor David Scott Miller

  73. Prognostic factors associated with overall survival in presumed early stage, high-grade serous ovarian cancer: an analysis of the SEER cancer database

    Article • Gynecologic Oncology, August 2021, Elsevier

    Professor David Scott Miller

  74. Stoma creation at the time of large bowel resection during ovarian cytoreductive surgery does not improve 30-day postoperative surgical outcomes

    Article • Gynecologic Oncology, August 2021, Elsevier

    Professor David Scott Miller

  75. Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC).

    Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  76. Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.

    Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  77. Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors

    Article • The Journal of Pathology, March 2021, Wiley

    Professor David Scott Miller

  78. Sex Hormone, Insulin and Insulin-like Growth Factor in Recurrence of High Stage Endometrial Cancer

    Article • Cancer Epidemiology Biomarkers & Prevention, February 2021, American Association for Cancer Research (AACR)

    Professor David Scott Miller, Gloria Huang

  79. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

    Article • Journal of the National Comprehensive Cancer Network, February 2021, Harborside Press, LLC

    Professor David Scott Miller

  80. Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery

    Article • Gynecologic Oncology Reports, November 2020, Elsevier

    Professor David Scott Miller

  81. Association between elapsed time after initial diagnosis and outcomes in patients diagnosed with early stage cervical cancer at a safety net hospital

    Article • Gynecologic Oncology, November 2020, Elsevier

    Professor David Scott Miller

  82. 125 Results of a randomized phase ii trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent chemonaive stromal ovarian tumors

    Article • November 2020, BMJ

    Professor David Scott Miller

  83. Comparing overall survival in women diagnosed and treated for a gynecological sarcoma at a private versus county hospital

    Article • Gynecologic Oncology, October 2020, Elsevier

    Professor David Scott Miller

  84. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

    Article • Journal of Clinical Oncology, September 2020, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  85. Stage IVA cervical cancer: outcomes of disease related complications and treatment

    Article • International Journal of Gynecological Cancer, September 2020, BMJ

    Professor David Scott Miller

  86. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma

    Article • International Journal of Radiation Oncology*Biology*Physics, September 2020, Elsevier

    Professor David Scott Miller

  87. Current Practice Patterns in Nodal Evaluation and Adjuvant Treatment of Advanced Stage Endometrioid Endometrial Cancer: an SGO Survey

    Article • Gynecologic Oncology Reports, August 2020, Elsevier

    Professor David Scott Miller

  88. Practice patterns using minimally invasive surgery for the treatment of ovarian cancer: A survey of physician members of the Society of Gynecologic Oncologists

    Article • Gynecologic Oncology Reports, August 2020, Elsevier

    Professor David Scott Miller

  89. Beyond Sedlis: A novel, histology-based nomogram for predicting recurrence risk and need for adjuvant radiation in cervical cancer—A NRG/GOG ancillary analysis.

    Article • Journal of Clinical Oncology, May 2020, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  90. Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery.

    Article • Journal of Clinical Oncology, May 2020, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  91. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma

    Article • The American Journal of Surgical Pathology, May 2020, Wolters Kluwer Health

    Professor David Scott Miller

  92. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

    Article • Gynecologic Oncology, May 2020, Elsevier

    Professor David Scott Miller

  93. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    Article • Journal of the National Comprehensive Cancer Network, April 2020, Harborside Press, LLC

    Professor David Scott Miller

  94. Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial

    Article • Gynecologic Oncology, March 2020, Elsevier

    Professor David Scott Miller

  95. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

    Article • Journal of Clinical Oncology, February 2020, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  96. Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group

    Article • Gynecologic Oncology, February 2020, Elsevier

    Professor David Scott Miller

  97. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

    Article • Gynecologic Oncology, February 2020, Elsevier

    Professor David Scott Miller

  98. Second-line lenvatinib in patients with recurrent endometrial cancer

    Article • Gynecologic Oncology, January 2020, Elsevier

    Professor David Scott Miller

  99. A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2019, Elsevier

    Professor David Scott Miller

  100. Phase Ib/IIa study assessing the safety and efficacy of adding AL3818 (anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma

    Article • Annals of Oncology, October 2019, Elsevier

    Professor David Scott Miller

  101. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncolog...

    Article • Gynecologic Oncology, July 2019, Elsevier

    Professor David Scott Miller

  102. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2019, New England Journal of Medicine (NEJM/MMS)

    Professor David Scott Miller

  103. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

    Article • The Lancet Oncology, June 2019, Elsevier

    Professor David Scott Miller

  104. Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

    Article • Gynecologic Oncology, June 2019, Elsevier

    Professor David Scott Miller

  105. A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  106. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  107. Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  108. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Article • The Lancet Oncology, May 2019, Elsevier

    Professor David Scott Miller

  109. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer

    Article • Journal of Clinical Oncology, April 2019, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  110. Reply to F. Tomao et al

    Article • Journal of Clinical Oncology, April 2019, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  111. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

    Article • Journal of Clinical Oncology, November 2018, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  112. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia

    Article • International Journal of Gynecological Pathology, October 2018, Wolters Kluwer Health

    Professor David Scott Miller

  113. QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

    Article • Annals of Oncology, October 2018, Elsevier

    Professor David Scott Miller

  114. GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

    Article • Gynecologic Oncology, June 2018, Elsevier

    Professor David Scott Miller

  115. Screening for Lynch syndrome in a medically underserved population

    Article • Gynecologic Oncology, June 2018, Elsevier

    Professor David Scott Miller

  116. QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  117. ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  118. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  119. Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, loc...

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  120. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer

    Article • American Journal of Clinical Oncology, May 2018, Wolters Kluwer Health

    Professor David Scott Miller

  121. Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration

    Article • American Journal of Clinical Oncology, April 2018, Wolters Kluwer Health

    Professor David Scott Miller

  122. Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer

    Article • American Journal of Clinical Oncology, March 2018, Wolters Kluwer Health

    Professor David Scott Miller

  123. Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer

    Article • Journal of Surgical Oncology, February 2018, Wiley

    Professor David Scott Miller

  124. Adenocarcinoma of the Uterine Corpus

    Article • January 2018, Elsevier

    Professor David Scott Miller

  125. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer

    Article • Gynecologic Oncology, January 2018, Elsevier

    Professor David Scott Miller

  126. Contributors

    Article • January 2018, Elsevier

    Professor David Scott Miller

  127. Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis

    Article • Urologic Oncology Seminars and Original Investigations, December 2017, Elsevier

    Professor David Scott Miller

  128. New therapies for advanced, recurrent, and metastatic endometrial cancers

    Article • Gynecologic Oncology Research and Practice, December 2017, Springer Science + Business Media

    Professor David Scott Miller

  129. A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2017, Elsevier

    Professor David Scott Miller

  130. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study

    Article • International Journal of Cancer, November 2017, Wiley

    Professor David Scott Miller

  131. Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses

    Article • Urology, November 2017, Elsevier

    Professor David Scott Miller

  132. Detection of Chronic Hepatitis B in Gynecologic Oncology Patients Undergoing Systemic Chemotherapy

    Article • Gynecologic Oncology, October 2017, Elsevier

    Professor David Scott Miller

  133. Family History of Cancer Shows Improved Survival in Uterine Papillary Serous Carcinoma

    Article • Gynecologic Oncology, October 2017, Elsevier

    Professor David Scott Miller

  134. Patients with Sarcopenia Benefit from Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

    Article • Gynecologic Oncology, October 2017, Elsevier

    Professor David Scott Miller

  135. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer

    Article • American Journal of Clinical Oncology, August 2017, Wolters Kluwer Health

    Professor David Scott Miller

  136. Long-Term Percutaneous Nephrostomy Management of Malignant Urinary Obstruction: Estimation of Optimal Exchange Frequency and Estimation of the Financial Impact of Patient Compliance

    Article • Journal of Vascular and Interventional Radiology, July 2017, Elsevier

    Professor David Scott Miller

  137. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol

    Article • Gynecologic Oncology, June 2017, Elsevier

    Professor David Scott Miller

  138. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study

    Article • Gynecologic Oncology, June 2017, Elsevier

    Professor David Scott Miller

  139. Weekly paclitaxel for recurrent ovarian cancer: Does weekly administration during primary therapy impact efficacy and toxicity at recurrence?

    Article • Gynecologic Oncology, June 2017, Elsevier

    Professor David Scott Miller

  140. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  141. Considering Closed Incision Negative Pressure Therapy for Obese Patients with Gynecologic Malignancies [31E]

    Article • Obstetrics and Gynecology, May 2017, Wolters Kluwer Health

    Professor David Scott Miller

  142. Description of Medium- and Long-Term Complications After PCN Placement for Malignant Urinary Obstruction [1J]

    Article • Obstetrics and Gynecology, May 2017, Wolters Kluwer Health

    Professor David Scott Miller

  143. Determination of Optimal Routine Exchange Frequency After PCN Placement for Malignant Urinary Obstruction [35E]

    Article • Obstetrics and Gynecology, May 2017, Wolters Kluwer Health

    Professor David Scott Miller

  144. Response to “Towards implementation of sexual healthcare”

    Article • Gynecologic Oncology Reports, April 2017, Elsevier

    Professor David Scott Miller

  145. Sparse feature selection for classification and prediction of metastasis in endometrial cancer

    Article • BMC Genomics, March 2017, Springer Science + Business Media

    Professor David Scott Miller

  146. Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma

    Article • American Journal of Clinical Oncology, February 2017, Wolters Kluwer Health

    Professor David Scott Miller

  147. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity

    Article • American Journal of Clinical Oncology, February 2017, Wolters Kluwer Health

    Professor David Scott Miller

  148. The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment

    Article • Gynecologic Oncology, January 2017, Elsevier

    Professor David Scott Miller

  149. Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery

    Article • Cancer, November 2016, Wiley

    Professor David Scott Miller

  150. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis

    Article • Gynecologic Oncology, November 2016, Elsevier

    Professor David Scott Miller

  151. Sparse Feature Selection for Classification and Prediction of Metastasis in Endometrial Cancer

    Article • October 2016, ACM (Association for Computing Machinery)

    Professor David Scott Miller, Professor Mathukumalli Vidyasagar

  152. Core muscle index is prognostic of survival in advanced ovarian cancers

    Article • Gynecologic Oncology, October 2016, Elsevier

    Professor David Scott Miller

  153. The Opinions and Practices of Providers Toward the Sexual Issues of Cervical Cancer Patients Undergoing Treatment

    Article • Gynecologic Oncology, October 2016, Elsevier

    Professor David Scott Miller

  154. Weekly Paclitaxel for Recurrent Ovarian Cancer: Does Weekly Administration at Primary Diagnosis Impact Efficacy and Toxicity at Recurrence?

    Article • Gynecologic Oncology, October 2016, Elsevier

    Professor David Scott Miller

  155. Prognostic Significance of Nodal Location in Stage IIIC Endometrial Carcinoma: Implications for Optimal Adjuvant Therapy

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2016, Elsevier

    Professor David Scott Miller

  156. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia

    Article • Obstetrics and Gynecology, September 2016, Wolters Kluwer Health

    Professor David Scott Miller

  157. Factors influencing primary treatment of midline vulvar cancers

    Article • Gynecologic Oncology, July 2016, Elsevier

    Professor David Scott Miller

  158. Locally Advanced Cervical Cancer

    Article • American Journal of Clinical Oncology, June 2016, Wolters Kluwer Health

    Professor David Scott Miller

  159. Adjuvant External Radiation is Essential in the Management of Pelvis-Limited Stage III Endometrial Carcinoma

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2015, Elsevier

    Professor David Scott Miller

  160. Anti-angiogenic treatment of cervical cancer significantly decreases new target lesions

    Article • Gynecologic Oncology, October 2015, Elsevier

    Professor David Scott Miller

  161. Defining optimal management of midline vulvar cancers

    Article • Gynecologic Oncology, October 2015, Elsevier

    Professor David Scott Miller

  162. Emphasis on systemic therapy for women with pelvic bone involvement at time of diagnosis of cervical cancer

    Article • Gynecologic Oncology, October 2015, Elsevier

    Professor David Scott Miller

  163. Locally advanced cervical cancer: Effect of radiation dosage and treatment duration on outcomes

    Article • Gynecologic Oncology, October 2015, Elsevier

    Professor David Scott Miller

  164. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment

    Article • Journal of Clinical Investigation, September 2015, American Society for Clinical Investigation

    Professor David Scott Miller

  165. Ovarian involvement in endometrioid adenocarcinoma of uterus

    Article • Gynecologic Oncology, September 2015, Elsevier

    Professor David Scott Miller

  166. Reply to W.A.A. Tjalma and J.S. Grossman

    Article • Journal of Clinical Oncology, February 2015, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  167. Factors Influencing Primary Treatment in Advanced Vulvar Cancer

    Article • Brachytherapy, January 2015, Elsevier

    Professor David Scott Miller

  168. Total Laparoscopic Radical Hysterectomy in the Obese Patient

    Article • Brachytherapy, January 2015, Elsevier

    Professor David Scott Miller

  169. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

    Article • Gynecologic Oncology, December 2014, Elsevier

    Professor David Scott Miller

  170. Cervical cancer — Distant failure after treatment of para-aortic lymph node metastases

    Article • Gynecologic Oncology, November 2014, Elsevier

    Professor David Scott Miller

  171. Isolated ovarian metastasis in endometrial adenocarcinoma of uterus

    Article • Gynecologic Oncology, November 2014, Elsevier

    Professor David Scott Miller

  172. Surgical and systemic management of endometrial cancer: an international survey

    Article • Archives of Gynecology and Obstetrics, October 2014, Springer Science + Business Media

    Professor David Scott Miller

  173. Adnexal masses requiring surgical intervention in women with advanced cervical cancer

    Article • Gynecologic Oncology, September 2014, Elsevier

    Professor David Scott Miller

  174. Factors associated with clinical trial screening failures in gynecologic oncology

    Article • Gynecologic Oncology, September 2014, Elsevier

    Professor David Scott Miller

  175. 2A phase II study to determine the response to second curettage as initial management for persistent “low-risk” non-metastatic gestational trophoblastic neoplasia: A Gynecologic Oncology Group study

    Article • Gynecologic Oncology, August 2014, Elsevier

    Professor David Scott Miller

  176. Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group

    Article • Journal of Clinical Oncology, July 2014, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  177. Malignant ovarian germ cell tumor — Role of surgical staging and gonadal dysgenesis

    Article • Gynecologic Oncology, July 2014, Elsevier

    Professor David Scott Miller

  178. ZoptEC: Phase III study of zoptarelin doxorubicin (AEZS-108) in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050).

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  179. The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline

    Article • Practical Radiation Oncology, May 2014, Elsevier

    Professor David Scott Miller

  180. Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer

    Article • Clinical Ovarian and Other Gynecologic Cancer, December 2013, Elsevier

    Professor David Scott Miller

  181. Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting

    Article • International Journal of Gynecological Cancer, October 2013, Wolters Kluwer Health

    Professor David Scott Miller

  182. Outcomes of phenotypic females with dysgerminoma and 46, XY karyotype

    Article • Gynecologic Oncology, October 2013, Elsevier

    Professor David Scott Miller

  183. Distinct microscopic features of perineural invasion in adenoid cystic carcinoma of the head and neck

    Article • Histopathology, August 2013, Wiley

    Professor David Scott Miller

  184. Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review

    Article • Modern Chemotherapy, January 2013, Scientific Research Publishing, Inc,

    Professor David Scott Miller

  185. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

    Article • Gynecologic Oncology, December 2012, Elsevier

    Professor David Scott Miller

  186. Clinical course of ovarian cancer after two salvage regimens

    Article • Gynecologic Oncology, October 2012, Elsevier

    Professor David Scott Miller

  187. Incidence of adnexal metastasis requiring surgical intervention in women with advanced cervical cancer

    Article • Gynecologic Oncology, October 2012, Elsevier

    Professor David Scott Miller

  188. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement

    Article • Gynecologic Oncology, October 2012, Elsevier

    Professor David Scott Miller

  189. Stage IIIC1 versus IIIC2 endometrial adenocarcinoma of the uterus: Analysis of recurrence and patterns of toxicity

    Article • Gynecologic Oncology, October 2012, Elsevier

    Professor David Scott Miller

  190. Survival outcomes after recurrence in endometrioid compared to papillary serous/clear cell carcinoma of the uterus

    Article • Gynecologic Oncology, October 2012, Elsevier

    Professor David Scott Miller

  191. Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

    Article • Gynecologic Oncology, June 2012, Elsevier

    Professor David Scott Miller

  192. Challenging prognostic factors for chemotherapy resistance in gestational trophoblastic neoplasia

    Article • Gynecologic Oncology, March 2012, Elsevier

    Professor David Scott Miller

  193. Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy

    Article • Gynecologic Oncology, March 2012, Elsevier

    Professor David Scott Miller

  194. Effect of BMI on progesterone therapy for endometrial cancer

    Article • Gynecologic Oncology, March 2012, Elsevier

    Professor David Scott Miller

  195. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?

    Article • American Journal of Obstetrics and Gynecology, March 2012, Elsevier

    Professor David Scott Miller

  196. Adenocarcinoma of the Uterine Corpus

    Article • January 2012, Elsevier

    Professor David Scott Miller

  197. Clinical Evidence: Metastases can Metastasize

    Article • World Journal of Oncology, January 2012, Elmer Press, Inc.

    Professor David Scott Miller

  198. Contributors

    Article • January 2012, Elsevier

    Professor David Scott Miller

  199. PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment

    Article • Clinical Ovarian Cancer, December 2011, Elsevier

    Professor David Scott Miller

  200. Challenging prognostic factors for chemotherapy resistance in high-risk gestational trophoblastic neoplasia

    Article • Gynecologic Oncology, November 2011, Elsevier

    Professor David Scott Miller

  201. Outcomes of third line chemotherapy for recurrent and persistent cervical cancer

    Article • Gynecologic Oncology, November 2011, Elsevier

    Professor David Scott Miller

  202. Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors

    Article • Gynecologic Oncology, November 2011, Elsevier

    Professor David Scott Miller

  203. Survival impact of clinical trials in patients with recurrent cervical cancer

    Article • Gynecologic Oncology, November 2011, Elsevier

    Professor David Scott Miller

  204. Does myometrial invasion confer a poorer prognosis in uterine adenosarcoma?

    Article • Gynecologic Oncology, November 2011, Elsevier

    Professor David Scott Miller

  205. The Role of Lymphadenectomy in Endometrial Cancer

    Article • Clinical Obstetrics & Gynecology, June 2011, Wolters Kluwer Health

    Professor David Scott Miller

  206. A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) women with locally advanced cervical cancer (CXCA): A GOG study.

    Article • Journal of Clinical Oncology, May 2011, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  207. Third-line salvage chemotherapy for recurrent cervical cancer.

    Article • Journal of Clinical Oncology, May 2011, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  208. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study

    Article • Gynecologic Oncology, April 2011, Elsevier

    Professor David Scott Miller

  209. At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis

    Article • Journal of Clinical Oncology, April 2011, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  210. Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study

    Article • Journal of Clinical Oncology, January 2011, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  211. PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment

    Article • Clinical Ovarian Cancer, November 2010, Elsevier

    Professor David Scott Miller

  212. Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?

    Article • Women s Health, November 2010, SAGE Publications

    Professor David Scott Miller

  213. A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer

    Article • International Journal of Gynecological Cancer, October 2010, BMJ

    Professor David Scott Miller

  214. The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.

    Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  215. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas

    Article • Gynecologic Oncology, May 2010, Elsevier

    Professor David Scott Miller

  216. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology

    Article • Gynecologic Oncology, December 2009, Elsevier

    Professor David Scott Miller

  217. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

    Article • Gynecologic Oncology, December 2009, Elsevier

    Professor David Scott Miller

  218. Epigenetic Repression of microRNA-129-2 Leads to Overexpression of SOX4 Oncogene in Endometrial Cancer

    Article • Cancer Research, November 2009, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  219. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer

    Article • Gynecologic Oncology, September 2009, Elsevier

    Professor David Scott Miller

  220. Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer

    Article • Gynecologic Oncology, August 2009, Elsevier

    Professor David Scott Miller

  221. Pharmacotherapy of endometrial cancer

    Article • Expert Opinion on Pharmacotherapy, July 2009, Informa Healthcare

    Professor David Scott Miller

  222. Recent Progress: Gynecologic Oncology Group Trials in Uterine Corpus Tumors

    Article • Reviews on Recent Clinical Trials, May 2009, Bentham Science Publishers

    Professor David Scott Miller

  223. Chemo- and Radiotherapy in Adjuvant Management of Optimally Debulked Endometrial Cancer

    Article • Journal of the National Comprehensive Cancer Network, May 2009, Harborside Press, LLC

    Professor David Scott Miller

  224. Somatic LKB1 Mutations Promote Cervical Cancer Progression

    Article • PLOS One, April 2009, PLOS

    Professor David Scott Miller

  225. Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

    Article • Journal of Clinical Oncology, March 2009, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  226. Endometrial Cancer State of the Science Meeting

    Article • International Journal of Gynecological Cancer, January 2009, BMJ

    Professor David Scott Miller

  227. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

    Article • Gynecologic Oncology, December 2008, Elsevier

    Professor David Scott Miller

  228. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

    Article • Gynecologic Oncology, July 2008, Elsevier

    Professor David Scott Miller

  229. Implications of EGFR inhibition in ovarian cancer cell proliferation

    Article • Gynecologic Oncology, June 2008, Elsevier

    Professor David Scott Miller

  230. A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  231. Gynecologic oncology group trials in uterine corpus malignancies: recent progress

    Article • Journal of Gynecologic Oncology, January 2008, Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy (KAMJE)

    Professor David Scott Miller

  232. Multi-institutional retrospective analysis of lymphadenectomy in early stage adenocarcinoma of the cervix

    Article • Gynecologic Oncology, November 2007, Elsevier

    Professor David Scott Miller

  233. Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix☆

    Article • Gynecologic Oncology, November 2007, Elsevier

    Professor David Scott Miller

  234. Secreted protein rich and acidic in cysteine (SPARC) as a predictor of cervical carcinogenesis and regulator of cervical cancer growth

    Article • Gynecologic Oncology, November 2007, Elsevier

    Professor David Scott Miller

  235. Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells

    Article • Reproductive Sciences, January 2007, SAGE Publications

    Professor David Scott Miller

  236. Gestational trophoblastic disease among Hispanic women: A 21-year hospital-based study

    Article • Gynecologic Oncology, October 2006, Elsevier

    Professor David Scott Miller

  237. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors

    Article • American Journal of Obstetrics and Gynecology, May 2006, Elsevier

    Professor David Scott Miller

  238. Advanced endometrial cancer: Is lymphadenectomy necessary or sufficient?

    Article • Gynecologic Oncology, May 2006, Elsevier

    Professor David Scott Miller

  239. ‘I think it's low self-esteem’. Teachers' judgements: a cautionary tale

    Article • Education 3-13, March 2006, Taylor & Francis

    Professor David Scott Miller

  240. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study

    Article • Gynecologic Oncology, March 2006, Elsevier

    Professor David Scott Miller

  241. Hormonal therapy in epithelial ovarian cancer

    Article • Expert Review of Anticancer Therapy, January 2006, Informa Healthcare

    Professor David Scott Miller

  242. Fertility-Sparing Surgery for Ovarian Low Malignant Potential Tumors

    Article • Obstetrical & Gynecological Survey, December 2005, Wolters Kluwer Health

    Professor David Scott Miller

  243. Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas

    Article • Obstetrics and Gynecology, December 2005, Wolters Kluwer Health

    Professor David Scott Miller

  244. Fertility-sparing surgery for ovarian low malignant potential tumors

    Article • Gynecologic Oncology, August 2005, Elsevier

    Professor David Scott Miller

  245. Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study

    Article • Gynecologic Oncology, August 2005, Elsevier

    Professor David Scott Miller

  246. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles

    Article • American Journal of Obstetrics and Gynecology, May 2005, Elsevier

    Professor David Scott Miller

  247. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study

    Article • Journal of Clinical Oncology, April 2005, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  248. Clinical applications of hormonal therapy in ovarian cancer

    Article • Current Treatment Options in Oncology, April 2005, Springer Science + Business Media

    Professor David Scott Miller

  249. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6–12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study

    Article • Gynecologic Oncology, March 2005, Elsevier

    Professor David Scott Miller

  250. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study

    Article • Gynecologic Oncology, January 2005, Elsevier

    Professor David Scott Miller

  251. Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies

    Article • Gynecologic Oncology, August 2004, Elsevier

    Professor David Scott Miller

  252. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

    Article • Journal of Clinical Oncology, August 2004, American Society of Clinical Oncology (ASCO)

    Professor David Scott Miller

  253. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development1

    Article • Journal of the Society for Gynecologic Investigation, July 2004, SAGE Publications

    Professor David Scott Miller

  254. Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

    Article • Clinical Cancer Research, May 2004, American Association for Cancer Research (AACR)

    Professor David Scott Miller

  255. Other primary malignancies in patients with uterine corpus malignancy

    Article • American Journal of Obstetrics and Gynecology, May 2004, Elsevier

    Professor David Scott Miller

  256. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis

    Article • American Journal of Obstetrics and Gynecology, March 2004, Elsevier

    Professor David Scott Miller

  257. P16 as a molecular biomarker of cervical adenocarcinoma

    Article • American Journal of Obstetrics and Gynecology, March 2004, Elsevier

    Professor David Scott Miller

  258. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

    Article • Gynecologic Oncology, February 2004, Elsevier

    Professor David Scott Miller

  259. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies

    Article • Cancer, January 2004, Wiley

    Professor David Scott Miller

  260. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma

    Article • Gynecologic Oncology, December 2003, Elsevier

    Professor David Scott Miller

  261. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma

    Article • Cancer, October 2003, Wiley

    Professor David Scott Miller

  262. Localized Retroperitoneal Lymphangioleiomyomatosis Mimicking Malignancy

    Article • Archives of Pathology & Laboratory Medicine, July 2003, Archives of Pathology and Laboratory Medicine

    Professor David Scott Miller

  263. Postmolar surveillance at a trophoblastic disease center that serves indigent women

    Article • American Journal of Obstetrics and Gynecology, May 2003, Elsevier

    Professor David Scott Miller

  264. Cervical adenocarcinoma survival among Hispanic and white women: A multicenter cohort study

    Article • American Journal of Obstetrics and Gynecology, March 2003, Elsevier

    Professor David Scott Miller

  265. A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Article • Gynecologic Oncology, December 2002, Elsevier

    Professor David Scott Miller

  266. Endocervical Curettage at Conization to Predict Residual Cervical Adenocarcinoma in Situ

    Article • Gynecologic Oncology, October 2002, Elsevier

    Professor David Scott Miller

  267. Urinary Bladder Cancer

    Article • Clinical Obstetrics & Gynecology, September 2002, Wolters Kluwer Health

    Professor David Scott Miller

  268. Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study

    Article • Gynecologic Oncology, June 2002, Elsevier

    Professor David Scott Miller

  269. Management of Low-Risk Gestational Trophoblastic Tumors in an Indigent Population

    Article • Obstetrics and Gynecology, April 2002, Wolters Kluwer Health

    Professor David Scott Miller

  270. Early-Stage Cervical Adenocarcinoma Treated by Surgical Intent: The Role of Para-aortic Lymph Node Dissection

    Article • Gynecologic Oncology, February 2002, Elsevier

    Professor David Scott Miller

  271. Stage IIB–IVB Cervical Adenocarcinoma: Prognostic Factors and Survival

    Article • Gynecologic Oncology, January 2002, Elsevier

    Professor David Scott Miller

  272. Correspondence

    Article • Acta Radiologica, December 2001, SAGE Publications

    Professor David Scott Miller

  273. Germline BRCA1–2 Mutations in Non-Ashkenazi Families with Double Primary Breast and Ovarian Cancer

    Article • Gynecologic Oncology, November 2001, Elsevier

    Professor David Scott Miller

  274. Intraoperative Lymphatic Mapping in Cervix Cancer Patients Undergoing Radical Hysterectomy: A Pilot Study

    Article • Gynecologic Oncology, November 2000, Elsevier

    Professor David Scott Miller

  275. Chromosome 4 Deletions Are Frequent in Invasive Cervical Cancer and Differ between Histologic Variants

    Article • Gynecologic Oncology, October 2000, Elsevier

    Professor David Scott Miller

  276. Phase II Trial of Topotecan in Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas

    Article • American Journal of Clinical Oncology, August 2000, Wolters Kluwer Health

    Professor David Scott Miller

  277. Adenomyofibroma of the Endometrium with Skeletal Muscle Differentiation

    Article • International Journal of Gynecological Pathology, July 2000, Wolters Kluwer Health

    Professor David Scott Miller

  278. Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients

    Article • Obstetrics and Gynecology, July 2000, Wolters Kluwer Health

    Professor David Scott Miller

  279. Bacteriology and Treatment of Malodorous Lower Reproductive Tract in Gynecologic Cancer Patients

    Article • Obstetrics and Gynecology, July 2000, Wolters Kluwer Health

    Professor David Scott Miller

  280. Endometrial Endometrioid Carcinomas Associated with Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

    Article • International Journal of Gynecological Pathology, April 2000, Wolters Kluwer Health

    Professor David Scott Miller

  281. Ectopic Production and Localization of ??-Human Chorionic Gonadotropin in Lymphoepithelioma-Like Carcinoma of the Cervix: A Case Report

    Article • International Journal of Gynecological Pathology, April 2000, Wolters Kluwer Health

    Professor David Scott Miller

  282. Uterine Metastasis from a Heterologous Metaplastic Breast Carcinoma Simulating a Primary Uterine Malignancy

    Article • Gynecologic Oncology, April 2000, Elsevier

    Professor David Scott Miller

  283. Role of TSG101 in Uterine Cervix Cancer

    Article • Gynecologic Oncology, December 1999, Elsevier

    Professor David Scott Miller

  284. The Ovarian Tumor Index predicts risk for malignancy

    Article • Cancer, December 1999, Wiley

    Professor David Scott Miller

  285. The Ovarian Tumor Index predicts risk for malignancy

    Article • Cancer, December 1999, Wiley

    Professor David Scott Miller

  286. Abdominal compartment syndrome in gynecologic surgery

    Article • Obstetrics and Gynecology, November 1999, Wolters Kluwer Health

    Professor David Scott Miller

  287. ABDOMINAL COMPARTMENT SYNDROME IN GYNECOLOGIC SURGERY

    Article • Obstetrics and Gynecology, November 1999, Wolters Kluwer Health

    Professor David Scott Miller

  288. Frequent Expression of β-Human Chorionic Gonadotropin (β-hCG) in Squamous Cell Carcinoma of the Cervix

    Article • International Journal of Gynecological Pathology, October 1999, Wolters Kluwer Health

    Professor David Scott Miller

  289. Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer

    Article • International Journal of Gynecological Cancer, September 1999, Wolters Kluwer Health

    Professor David Scott Miller

  290. Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas

    Article • Journal of the Society for Gynecologic Investigation, July 1999, SAGE Publications

    Professor David Scott Miller

  291. Genetic Changes During the Multistage Pathogenesis of Human Papiloomavirus Positive and Negative Vulvar Carcinomas

    Article • Journal of the Society for Gynecologic Investigation, July 1999, Springer Science + Business Media

    Professor David Scott Miller

  292. Does Glutamine Supplementation Increase Radioresistance in Squamous Cell Carcinoma of the Cervix?

    Article • Gynecologic Oncology, December 1998, Elsevier

    Professor David Scott Miller

  293. In VivoStudies of Adenovirus-Based p53 Gene Therapy for Ovarian Cancer

    Article • Gynecologic Oncology, June 1998, Elsevier

    Professor David Scott Miller

  294. Pathology Slide Review in Gynecologic Oncology

    Article • Obstetrics and Gynecology, May 1998, Wolters Kluwer Health

    Professor David Scott Miller

  295. Abnormalities of Fragile Histidine Triad Genomic and Complementary DNAs in Cervical Cancer: Association With Human Papillomavirus Type

    Article • JNCI Journal of the National Cancer Institute, March 1998, Oxford University Press (OUP)

    Professor David Scott Miller

  296. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers

    Article • Human Molecular Genetics, February 1998, Oxford University Press (OUP)

    Professor David Scott Miller

  297. Preinvasive and Invasive Breast and Cervical Cancer Prior to or During Pregnancy

    Article • Clinics in Perinatology, June 1997, Elsevier

    Professor David Scott Miller

  298. Immunologic characterization of tumor markers in human ovarian cancer cell lines

    Article • Journal of the Society for Gynecologic Investigation, July 1996, SAGE Publications

    Professor David Scott Miller

  299. Immunologic Characterization of Tumor Markers in Human Ovarian Cancer Cell Lines

    Article • Journal of the Society for Gynecologic Investigation, July 1996, Springer Science + Business Media

    Professor David Scott Miller

  300. Long-term results of interstitial implant in locally advanced cervical cancer:A retrospective study of 50 cases

    Article • Radiation Oncology Investigations, January 1996, Wiley

    Professor David Scott Miller

  301. Adenovirus-Based p53 Gene Therapy in Ovarian Cancer

    Article • Gynecologic Oncology, November 1995, Elsevier

    Professor David Scott Miller

  302. Transfusion Medicine in Obstetrics and Gynecology

    Article • Obstetrical & Gynecological Survey, June 1995, Wolters Kluwer Health

    Professor David Scott Miller

  303. The Effect of Naproxen on Fever in Patients with Advanced Gynecologic Malignancies

    Article • Gynecologic Oncology, February 1995, Elsevier

    Professor David Scott Miller

  304. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors

    Article • The Journal of Clinical Endocrinology & Metabolism, December 1994, Endocrine Society

    Professor David Scott Miller

  305. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors.

    Article • The Journal of Clinical Endocrinology & Metabolism, December 1994, Endocrine Society

    Professor David Scott Miller

  306. Schistosomiasis and cervical cancer in Ghana

    Article • International Journal of Gynecology & Obstetrics, August 1993, Wiley

    Professor David Scott Miller

  307. DNA Flow Cytometric Analysis of Clinical Stage I Endometrial Carcinomas with Lymph Node Metastases

    Article • Gynecologic Oncology, July 1993, Elsevier

    Professor David Scott Miller

  308. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease

    Article • International Journal of Gynecology & Obstetrics, July 1993, Wiley

    Professor David Scott Miller

  309. A Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma

    Article • American Journal of Clinical Oncology, April 1992, Wolters Kluwer Health

    Professor David Scott Miller

  310. EMA-CO Chemotherapy: A well-tolerated and highly effective regimen for high-risk metastatic gestational trophoblastic disease

    Article • Gynecologic Oncology, April 1992, Elsevier

    Professor David Scott Miller

  311. Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer

    Article • Cancer, January 1992, Wiley

    Professor David Scott Miller

  312. Tumor size in endometrial cancer

    Article • Cancer, June 1991, Wiley

    Professor David Scott Miller

  313. Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma

    Article • Gynecologic Oncology, April 1991, Elsevier

    Professor David Scott Miller

  314. Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on multivariate analysis

    Article • American Journal of Obstetrics and Gynecology, February 1991, Elsevier

    Professor David Scott Miller

  315. Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies

    Article • Gynecologic Oncology, October 1990, Elsevier

    Professor David Scott Miller

  316. Correspondence

    Article • Gynecologic Oncology, August 1990, Elsevier

    Professor David Scott Miller

  317. Flow cytometric evaluation of epithelial ovarian cancer

    Article • American Journal of Obstetrics and Gynecology, June 1990, Elsevier

    Professor David Scott Miller

  318. Classification and Staging of Gestational Trophoblastic Tumors

    Article • Obstetrics and Gynecology Clinics of North America, September 1988, Elsevier

    Professor David Scott Miller

  319. Critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. III. Factors associated with persistent disease-free status and recurrence after “negative” operation

    Article • Gynecologic Oncology, January 1988, Elsevier

    Professor David Scott Miller

  320. Epithelial ovarian carcinoma in patients with intersex disorders: The role of pituitary gonadotropins in ovarian tumorigenesis

    Article • Gynecologic Oncology, July 1986, Elsevier

    Professor David Scott Miller

  321. A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma

    Article • Cancer, February 1986, Wiley

    Professor David Scott Miller

  322. Critical reassessment of “second-look” exploratory laparotomy in epithelial ovarian cancer. II. Prognostic factors and treatment outcome in patients with persistent cancer

    Article • Gynecologic Oncology, February 1986, Elsevier

    Professor David Scott Miller

  323. Cytotoxic properties of a mitochondrial specific label for gynecologic malignancies

    Article • Gynecologic Oncology, February 1986, Elsevier

    Professor David Scott Miller

  324. Psychosocial Variables and the Course of Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 1985, New England Journal of Medicine (NEJM/MMS)

    Professor David Scott Miller

  325. Psychosocial Correlates of Survival in Advanced Malignant Disease?

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 1985, New England Journal of Medicine (NEJM/MMS)

    Professor David Scott Miller

  326. A psychological analysis of cancer patients and their next-of-kin

    Article • Cancer, January 1985, Wiley

    Professor David Scott Miller

  327. Psychosocial Status in Chronic Illness

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 1984, New England Journal of Medicine (NEJM/MMS)

    Professor David Scott Miller

  328. Psychosocial Status in Chronic Illness

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 1984, New England Journal of Medicine (NEJM/MMS)

    Professor David Scott Miller

  329. Pulsatile Administration of Low-Dose Gonadotropin-Releasing Hormone. Ovulation and Pregnancy in Women with Hypothalamic Amenorrhea

    Article • Obstetrical & Gynecological Survey, May 1984, Wolters Kluwer Health

    Professor David Scott Miller

  330. Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea

    Article • JAMA, December 1983, American Medical Association (AMA)

    Professor David Scott Miller

  331. Pulsatile Administration of Low-Dose Gonadotropin-Releasing Hormone

    Article • JAMA, December 1983, American Medical Association (AMA)

    Professor David Scott Miller

  332. Attitudes Toward Clinical Trials Among Patients and the Public

    Article • JAMA, August 1982, American Medical Association (AMA)

    Professor David Scott Miller

  333. Attitudes toward clinical trials among patients and the public

    Article • JAMA, August 1982, American Medical Association (AMA)

    Professor David Scott Miller

  334. CONTRIBUTORS

    Article • January 1980, Elsevier

    Professor David Scott Miller